The Role of Nurses in the Management and Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients Receiving Chemotherapy
Keywords:
Nursing roles, Care and prevention, Hand-foot syndrome, Colorectal cancer patients, ChemotherapyAbstract
Hand-Foot Syndrome (HFS) is a common complication in colorectal cancer patients undergoing chemotherapy, particularly with capecitabine and 5-fluorouracil. The symptoms of HFS significantly affect patients' quality of life, starting with redness, swelling, and pain in the palms and soles of the feet. These symptoms can be severe enough to affect daily activities and work. Studies have indicated that the prevalence of HFS in patients receiving capecitabine is as high as 49.1%. Several risk factors are associated with the development of HFS, including tumor type, chemotherapy regimen, age, and serum albumin levels. The role of nurses in managing Hand-Foot Syndrome (HFS) is crucial. Nurses should adopt a comprehensive care approach tailored to symptom severity, ranging from providing education on initial prevention strategies to proactive management in cases of severe symptoms. Furthermore, the integration of new technologies for monitoring and tracking HFS symptoms, such as symptom-tracking applications and wearable devices, enhances nurses' ability to assess and adjust treatment plans according to patient needs. Effective management of HFS not only alleviates symptoms and improves patients' quality of life but also promotes recovery and enhances overall well-being.
References
Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020;14(1):442-49.
King TL, Voon PJ, Yuen KH, Mohamed Noor DA. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia. Support Care Cancer. 2024;32(6):345-55.
Gialaim Purcino Dos Reis FC, Menêses AG, Mazoni SR, Pereira Silveira RCC, Diniz Dos Reis PE, Vasques CI. Topical interventions for preventing hand-foot syndrome resulting from antineoplastic therapy: A scoping review. Rev Esc Enferm USP. 2023;57(2):220-32.
Macedo LT, Lima JP, dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer. 2014;22(6):1585-93.
Vanumu DS, Kodisharapu PK, Suvvari P, Rayani BK, Pathi N, Tewani R, et al. Optimizing quality of life: integrating palliative care for patients with hand-foot syndrome in oncology practice. BMJ Support Palliat Care. 2024. ;35(5):168-78.
Eroğlu İ, Kutlutürkan S. The effect of hand-foot exercises on chemotherapy-induced peripheral neuropathy-related pain, falls, and quality of life in colorectal cancer: A randomized controlled trial. Eur J Oncol Nurs. 2024;71(1):1026-41.
De With M, van Doorn L, Maasland DC, Mulder TAM, Oomen-de Hoop E, Mostert B, et al. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD. Biomed Pharmacother. 2023;15(9):1142-52.
Milano G, Etienne-Grimaldi MC, Mari M, Lassalle S, Formento JL, Francoual M, et al. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol. 2008;66(1):88-95.
Huang J, Ye S, Feng S, Zheng M, Zhong M. Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2023;38(1):61-71.
De Queiroz MVR, de Medeiros A, Toledo SP, de Abreu Sarmenghi KD, de Vasconcellos VF. Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation. Ecancermedicalscience. 2022;16(3):1390-99.
Kanbayashi Y, Taguchi T, Ishikawa T, Otsuji E, Takayama K. Risk factors of capecitabine-induced hand-foot syndrome: A single-institution, retrospective study. Oncology. 2023;11(7):407-14.
Han CJ, Yang GS, Syrjala K. Symptom experiences in colorectal cancer survivors after cancer treatments: A systematic review and meta-analysis. Cancer Nurs. 2020;43(3):132-58.
Romero-Elías M, González-Cutre D, Beltrán-Carrillo VJ, Jiménez-Loaisa A. Beyond basic psychological needs: The hope construct during adjuvant treatment in colorectal cancer patients. Curr Psychol. 2023;42(4):2788-96.
Urakawa R, Tarutani M, Kubota K, Uejima E. Hand-foot syndrome has the strongest impact on QOL in skin toxicities of chemotherapy. J Cancer. 2019;10(20):4846-51.
Saif MW, Elfiky AA. Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients. J Support Oncol. 2007;5(7):337-43.
Degen A, Alter M, Schenck F, Satzger I, Völker B, Kapp A, et al. The hand-foot syndrome associated with medical tumor therapy – classification and management. JDDG: J Dtsch Dermatol Ges. 2010;8(9):652-61.
Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006;12(3):131-41.
Lian S, Zhang X, Zhang Y, Zhao Q. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: A meta-analysis. Clin Exp Dermatol. 2021;46(4):629-35.
Shaffer KM, Turner KL, Siwik C, Gonzalez BD, Upasani R, Glazer JV, et al. Digital health and telehealth in cancer care: a scoping review of reviews. Lancet Digit Health. 2023;5(5):316-27.
Coriat R, Sibaud V, Bourgeois V, Manfredi S, Artru P, Trouilloud I, et al. Digital tool to identify and monitor regorafenib-associated hand-foot skin reactions: A proof-of-concept study protocol. Dig Liver Dis. 2023;55(8):1019-25.
Huang Y, Upadhyay U, Dhar E, Kuo L-J, Syed-Abdul S. A scoping review to assess adherence to and clinical outcomes of wearable devices in the cancer population. Cancers (Basel). 2022;14(18):443-55.
Darley A, Coughlan B, Maguire R, McCann L, Furlong E. A bridge from uncertainty to understanding: The meaning of symptom management digital health technology during cancer treatment. Digit Health. 2023;9(4):205-215.
Husebø ALM, Søreide JA, Kørner H, Storm M, Wathne HB, Richardson A, et al. eHealth interventions to support colorectal cancer patients’ self-management after discharge from surgery an integrative literature review. Support Care Cancer. 2023;32(1):11-20.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Thammasat University Hospital Journal Online
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
